Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat

Neuroscience

Volumn 74, Issue 4, 1996, Pages 971-983

  Barneoud P ^a   Mazadier, M ^a   Miquet, J M ^a   Parmentier, S ^a   Dubedat P ^a   Doble, A ^a   Boireau, A ^a  

^a SANOFI   (France)

Author keywords

6 Hydroxydopamine; Dopaminergic metabolism; Neuroprotection; Rat; Rotation; Skilled paw use

Indexed keywords

AMPHETAMINE; APOMORPHINE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; RILUZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; LOCOMOTION; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0030271253     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(96)00249-7     Document Type: Article

References (78)

1. 1. Abrous D. N. and Dunnett S. B. (1994) Paw reaching in rats: the staircase test. Neurosci. Protoc. 10, 1-11.
2. 2. Abrous D. N., Torres E. M. and Dunnett S. B. (1993) Dopaminergic grafts implanted into the neonatal or adult striatum: comparative effects on rotation and paw reaching deficits induced by subsequent unilateral nigrostriatal lesions in adulthood. Neuroscience 54, 657-658.
3. 3. Abrous D. N., Wareham A. T., Torres E. M. and Dunnett S. B. (1992) Unilateral dopamine lesions in neonatal, weanling and adult rats: comparisons of rotation and reaching deficits. Behav. Brain Res. 51, 67-75.
4. 4. Agid Y., Javoy F. and Glowinski J. (1973) Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature 245, 150-151.
5. 5. Ambani L. M., Van Woert H. and Murphy S. (1974) Brain peroxidase and catalase in Parkinson's disease. Archs Neurol. 32, 114-118.
6. 6. Armstrong M., Daly A. K., Cholerton S., Bateman D. N. and Idle J. R. (1992) Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339, 1017-1018.
7. 7. Barnéoud P., Parmentier S., Mazadier M., Miquet J. M., Boireau A., Dubédat P. and Blanchard J.-C. (1995) Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neuroscience 67, 837-848.
8. 8. Benavides J., Camelin J. C., Mitrani N., Flamand F., Uzan A., Legrand J. J., Guérémy C. and Le Fur G. (1985) 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. II. Neuropharmacology 24, 1085-1092.
9. 9. Benazzouz A., Boraud T., Dubédat P., Boireau A., Stutzmann J.-M. and Gross C. (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J. Pharmac. 284, 299-307.
10. 10. Benoît E. and Escande D. (1991) Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflügers Arch. 361, 1-7.
11. 11. Ben-Sachar D., Zuk R. and Glinka Y. (1995) Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64, 718-723.
12. 12. Bensimon G., Lacomblez L., Meininger V. and the ALS/Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl. J. Med. 330, 585-601.
13. 13. Björklund A., Dunnett S. B., Stenevi U., Lewis M. E. and Iversen S. (1980) Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 199, 307-333.
14. 14. Boireau A., Dubédat P., Bordier F., Peny C., Miquet J.-M., Durand G., Meunier M. and Doble A. (1994) Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. NeuroReport 5, 2657-2660.
15. 15. Boireau A., Miquet J.-M., Dubédat P., Meunier M. and Doble A. (1994) Riluzole and experimental parkinsonism: partial antagonism of MPP+-induced increase in striatal extracellular dopamine in rats in vivo. NeuroReport 5, 2157-2160.
16. 16. Cadet J. L., Katz M., Jackson-Lewis V. and Fahn S. (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476, 10-15.
17. 17. Carman L. S., Gage F. H. and Shults C. W. (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res. 553, 275-283.
18. 18. Chéramy A., Barbeito L., Godeheu G. and Glowinski J. (1992) Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci. Lett. 147, 209-212.
19. 19. Chéramy A., Romo R., Godeheu G., Baruch P. and Glowinski J. (1986) In vivo presynaptic control of dopamine release in the cat caudate nucleus II. Facilitory or inhibitory influence of L-glutamate. Neuroscience 9, 1080-1090.
20. 20. Debono M. W., Le Guern J., Canton T., Doble A. and Pradier L. (1993) Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. J. Pharmac. 235, 283-289.
21. 3H]aspartate release from cultured cerebellar granule cells. Neurosci. Lett. 140, 251-254.
22. 22. Drejer J., Honoré T., Meier E. and Schousboe A. (1986) Pharmacologically distinct glutamate receptors on cerebellar granule cells. Life Sci. 38, 2077-2085.
23. 23. Dunnett S. B., Björklund A., Stenevi U. and Iversen S. (1981) Behavioral recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Res. 215, 147-161.
24. 24. Dunnett S. B., Whishaw I. Q., Rogers D. C. and Jones G. H. (1987) Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6-OHDA lesions. Brain Res. 415, 63-78.
25. 25. Freed C. R., Breeze R. E. and Rosenberg N. L. and Schneck S. A. (1993) Embryonic dopamine cell implants as a treatment for the second phase of Parkinson's disease. In Advances in Neurology: Parkinson's Disease from Basic Research to Treatment (eds Narabayashi H., Nagatsu T., Yanagisawa N. and Mizuno Y.), Vol. 60, pp. 721-728. Raven Press, New York.
26. 26. Gong L., Daigneault E. A., Acuff R. V. and Kostrewa R. M. (1991) Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. NeuroReport 2, 544-546.
27. 27. Harding A. E. (1993) Movement Disorders. In Brain Disease of the Nervous System (ed. Walton J.), pp. 395-401. Oxford University Press, New York.
28. 28. Hefti F., Melamed E., Sahakian B. J. and Wurtman R. J. (1980) Circling behavior in rats with partial, unilateral nigrostriatal lesions: effect of amphetamine, apomorphine, and dopa. Pharmac. Biochem. Behav. 12, 185-188.
29. 29. Heikkila R. and Cohen G. (1972) Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine: potentiation by ascorbic acid. Molec. Pharmac. 8, 241-248.
30. 30. Herman J. P. and Abrous N. (1993) Dopaminergic neural grafts after 15 years: results and perspectives. Prog. Neurobiol. 44, 1-35.
31. 31. Herman J. P., Choulli K. and Le Moal M. (1985) Hyper-reactivity to amphetamine in rats with dopaminergic grafts. Expl Brain Res. 60, 521-526.
32. 32. Hétier E., Boireau A., Dubédat P. and Blanchard J.-C. (1988) Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. Naunyn-Schmiedeberg's Arch. Pharmac. 337, 13-17.
33. 33. Hirsch E. C., Brandel J. P., Galle P., Javoy-Agid F. and Agid Y. (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56, 446-451.
34. 34. Hubert J. P., Delumeau J. C., Glowinski J., Prémont J. and Doble A. (1994) Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br. J. Pharmac. 113, 261-267.
35. 3H]aspartate release from cultured cerebellar granule cells. Neurosci. Lett. 96, 345-350.
36. 36. Hudson J. L., Van Horne C. G. and Stomberg I. (1993) Correlation of apomorphine-and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626, 167-174.
37. 37. Kish S. J., Morito C. and Hornykiewicz O. (1985) Glutathione peroxidase activity in Parkinson's disease. Neurosci. Lett. 58, 343-346.
38. 38. Kupsch A., Löschmann P. A., Sauer H., Arnold G., Renner P., Pufal D., Burg M., Wachtel H., Bruggencate G. and Oertel W. H. (1992) Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res. 592, 74-83.
39. 39. Lavielle S., Tassin J.-P., Thierry A.-M., Blanc G., Hervé D., Barthelemey C. and Glowinski J. (1978) Blockade by benzodiazepines of the selective high increase in dopamine turnover induced by stress in mesocortical dopaminergic neurons in the rat. Brain Res. 168, 585-594.
40. 40. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K. L., Sawle G., Rothwell J. C., Marsden C. D. and Björklund A. (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247, 574-577.
41. 41. Malgouris C., Bardot F., Daniel M., Pellis F., Rataud J., Uzan A., Blanchard J.-C. and Laduron P. M. (1989) Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J. Neurosci. 9, 3720-3727.
42. 42. Martinovits G., Melamed E., Cohen O., Rosenthal J. and Uzzan A. (1986) Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurosci. Lett. 69, 192-197.
43. 43. Michel P. P. and Agid Y. (1992) The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures. Brain Res. 597, 233-240.
44. 44. Miklyaeva E. I., Castañeda E. and Whishaw I. Q. (1995) Skilled reaching deficit in unilateral dopamine-depleted rats: Impairments in movement and posture and compensatory adjustments. J. Neurosci. 14, 7148-7158.
45. 45. Miller R. and Beninger R. J. (1991) On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine. Prog. Neurobiol. 36, 229-256.
46. 46. Mizoule J., Meldrum B., Mazadier M., Croucher M., Ollat C., Uzan A., Legrand J.-J., Gueremy C. and Le Fur G. (1985) 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties. Neuropharmacology 24, 767-773.
47. 47. Montoya C. P., Astell S. and Dunnett S. B. (1990) Effect of nigral and striatal grafts on skilled forelimb use in the rat. Prog. Brain Res. 82, 459-466.
48. 48. Montoya C. P., Campbell-Hope L. J. and Dunnett S. B. (1991) The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats. J. Neurosci. Meth. 36, 219-228.
49. 49. Mytilineou C., Han S. K. and Cohen G. (1993) Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J. Neurochem. 61, 1470-1478.
50. 50. Nikkhah G., Duan W. M., Knappe U., Jödike A. and Björklund A. (1993) Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model. Neuroscience 56, 33-43.
51. 51. Olney J. W., Zorumski C. F., Stewart G. R., Price M. T., Wang G. and Labruyere J. (1990) Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson's and Huntington's disease. Expl Neurol. 108, 269-272.
52. 52. Perry T. L., Yong V. W., Clavier R. M., Jones K., Wright J. M., Foulkes J. G. and Wall R. A. (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60, 109-114.
53. 53. Pratt J., Rataud J., Bardot F., Roux M., Blanchard J.-C., Laduron P. M. and Stutzmann J.-M. (1992) Neuroprotective actions of riluzole in rodent models of global and focal ischemia. Neurosci. Lett. 140, 225-230.
54. 54. Robinson T. E., Castaneda E. and Whishaw I. Q. (1990) Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or metamphetamine: a review of evidence for microdialysis studies. Can. J. Psychol. 44, 253-275.
55. 55. Robinson T. E., Moscary Z., Camp D. M. and Whishaw I. Q. (1994) Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. J. Neurosci. 14, 2687-2696.
56. 56. Robinson T. E. and Whishaw I. Q. (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res. 450, 209-224.
57. 57. Sachs C. H. and Jonsson G. (1975) Mechanisms of action of 6-hydroxydopamine. Pharmacology 24, 1-8.
58. 58. Samuel D., Blin O., Dusticier N. and Nieoullon A. (1992) Effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to dopamine, choline, GABA and glutamate synaptosomal high affinity uptake systems. Fundam. clin. Pharmac. 6, 177-184.
59. 59. Shapira A. H. V., Cooper J. M., Dexter D., Jenner P., Clark J. B. and Marsden C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet i, 1269.
60. 60. Siegfried B. and Bures J. (1980) Handedness in rats: blockade of reaching behavior by unilateral 6-OHDA injections into substantia nigra and caudate nucleus. Physiol. Psychol. 8, 360-368.
61. 61. Smith C. A., Gough A. C., Leigh P. J., Nigel Leigh P., Summers B. A., Harding A. E., Maranganore D. M., Sturman S. G., Schapira A. H. V., Williams A. C., Spurr N. K. and Wolf C. R. (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339, 1375-1377.
62. 62. Sonsalla P. K., Zeevalk G. D., Manzino L., Giovanni A. and Nicklas W. J. (1992) MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J. Neurochem. 58, 1979-1982.
63. 63. Spencer Smith T., Parker W. D. Jr and Bennett J. P. Jr (1994) L-DOPA increases nigral production of hydroxyl radicals in vivo: potential L-DOPA toxicity? NeuroReport 5, 1009-1011.
64. 64. Stutzmann J.-M., Bhöme G. A., Gandolfo G., Gottesmann C., Lafforgue J., Blanchard J.-C., Laduron P. M. and Lazdunski M. (1991) Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat. Eur. J. Pharmac. 193, 223-229.
65. 65. Stutzmann J.-M. and Doble A. (1994) Blockade of glutamatergic transmission and neuroprotection: the strange case of riluzole. In Neurodegenerative Diseases (eds Jolles G. and Stutzmann J.-M.), pp. 205-214. Academic Press, New York.
66. 66. Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.
67. 67. Turski L., Bressier K., Rettig K.-J., Löschmann P.-A. and Wachtel H. (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414-418.
68. 68. Ungerstedt U. (1971) Postsynaptic supersensitivity after 6-OHDA induced degeneration of the nigrostriatal dopamine system. Acta physiol. scand. 367, 69-93.
69. 69. Ungerstedt U. and Arbuthnott G. W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493.
70. 70. Whishaw I. Q., Castaneda E. and Gorny B. (1992) Dopamine and skilled limb use in the rat: more severe bilateral impairments follow substantia nigra than sensorimotor cortex 6-OHDA injection. Behav. Brain Res. 47, 89-92.
71. 71. Whishaw I. Q., Gorny B., Tran-Nguyen L. T. L., Castaneda E., Miklyaeva E. I. and Pellis S. M. (1994) Making two movements at once: impairments of movement, posture, and their integration underlie the adult skilled reaching deficit of neonatally dopamine-depleted rats. Behav. Brain Res. 61, 65-77.
72. 72. Whishaw I. Q., O'Connor W. T. and Dunnett S. B. (1986) The contributions of motor cortex, nigrostriatal dopamine and caudate-putamen to skilled forelimb use in the rat. Brain 109, 805-843.
73. 73. Whishaw I. Q., Pellis S. M. and Gorny B. P. (1992) Skilled reaching in rats and humans: evidence for parallel development or homology. Behav. Brain Res. 47, 59-70.
74. 74. Widner H., Tetrud J., Rehncrona S., Snow B. J., Brundin P., Björklund A. and Lindvall O. and Langston J. W. (1993) Fifteen month's follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism. In Advances in Neurology: Parkinson's Disease from Basic Research to Treatment (eds Narabayashi H., Nagatsu T., Yanagisawa N. and Mizuno Y.), Vol. 60, pp. 729-733. Raven Press, New York.
75. 75. Youdim M. B. H., Ben-Sachar D. and Riederer P. (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced degeneration? Acta neurol. scand. 126, 47-54.
76. 76. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A. and Stricker E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290-296.
77. 77. Zigmond M. J. and Stricker E. M. (1989) Animal models of Parkinsonism using selective neurotoxins: clinical and basic implications. Int. Rev. Neurobiol. 31, 1-79.
78. 78. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F. and Corsini G. (1992) MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J. Neurochem. 59, 733-739.